In addition, eribulin has been shown to increase the population of CD103+ T lymphocytes and subsequent activation by upregulating the expression of E-cadherin on cancer cells in a murine model of lung cancer, melanoma, and bladder cancer [38]. The gene discussed is CDH1; the disease is urinary bladder carcinoma.